New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

In both trials, TransCon PTH was generally well tolerated, with no new safety signals identified. Most treatment-emergent adverse events (TEAEs) were mild to moderate (Grade 1 or 2) and no patients ...
Rutgers University

Landmark Data from Rutgers Cancer Institute and RWJBarnabas Health Show Long-term Complete Responses of T Cell Therapies for HPV-Related Cancers

Researchers from Rutgers Cancer Institute, New Jersey’s only National Cancer Institute (NCI) - designated Comprehensive ...